You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Monday, December 4, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
       
       

      CPD

      Molecularly Guided Therapies for Metastatic Colorectal Cancer: Choose Your Marker to Treat

      • Authors: Julien Taieb, MD, PhD; Chiara Cremolini, MD, PhD; Harpreet Wasan, MD; Eric Van Cutsem, MD, PhD; Sebastian Stintzing, MD
      • CPD Released: 4/5/2023
      • Valid for credit through: 4/5/2024, 11:59 PM EST
      Start Activity

      • Credits Available

        Non-US Physicians - maximum of 0.50 CPD

        You Are Eligible For

        • Letter of Completion

      Target Audience and Goal Statement

      This activity is intended for an international audience of non-US healthcare professionals, specifically gastroenterologists, hematology/oncology specialists, pathologists, and any other healthcare specialists involved in the care of patients with metastatic colorectal cancer (mCRC).

      The goal of this activity is for learners to be better able to apply molecular testing in their patients with mCRC and use the results to inform treatment strategies with current and emerging targeted therapies.

      Upon completion of this activity, participants will:

      • Have increased knowledge regarding the
        • Molecular testing requirements in patients with mCRC
        • Impact of RAS mutation status on the treatment of mCRC
        • Available clinical data with targeted therapies for human epidermal growth factor receptor 2 (HER2)-amplified mCRC
      • Have greater competence related to
        • Selecting therapy according to BRAF mutation status in a patient with mCRC
        • Selecting therapy according to microsatellite instability/mismatch repair deficient (MSI/dMMR) status in a patient with mCRC
        • Selecting therapy in patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive mCRC

      Disclosures

      WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

      All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

      Faculty

      • Julien Taieb, MD, PhD

        Professor
        Université Paris Cite (Descartes)
        Hôpital Européen Georges-Pompidou
        Paris, France

        Disclosures

        Julien Taieb, MD, PhD has the following relevant financial relationships:
        Consultant or advisor for: AstraZeneca; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Merck Sharp & Dohme; Merck; Novartis; Pierre Fabre; Roche; SERVIER
        peaker or member of speakers bureau for: AstraZeneca; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Merck Sharp & Dohme; Merck; Novartis; Pierre Fabre; Roche; SERVIER
        Research funding from: Pierre Fabre

      • Chiara Cremolini, MD, PhD

        Professor of Medical Oncology
        University of Pisa
        Pisa, Italy

        Disclosures

        Chiara Cremolini, MD, PhD has the following relevant financial relationships:
        Consultant or advisor for: Amgen Inc.; Merck; Pierre Fabre; SERVIER; Nordic Pharma
        Speaker or member of speakers bureau for: Bayer; Merck Sharp & Dohme; SERVIER; Pierre Fabre
        Research funding from: Bayer; Merck; SERVIER

      • Harpreet Wasan, MD

        Professor and Consultant in Medical Oncology
        Division of Cancer
        Hammersmith Hospital
        Imperial College Healthcare London
        London, United Kingdom

        Disclosures

        Harpreet Wasan, MD, has the following relevant financial relationships:
        Consultant or advisor for: ARCAD (Pancreas Academic); Bayer; Bristol Myers Squibb Company (Celgene Corporation); BTG International Ltd.; Celgene Corporation; Erytech Pharma; FM; Genentech; Incyte Corporation; NICE/BSI expert; Merck KGaA; ONCOSIL; SERVIER; SIRTEX Medical; Roche; Pierre Fabre; Pfizer, Inc.; Zymeworks
        Speaker or member of speakers bureau for: Bayer; Bristol Myers Squibb Company (Celgene Corporation); BTG International Ltd.; Erytech Pharma; FM; Genentech; Incyte Corporation; Merck KGaA; Roche; SERVIER; SIRTEX Medical; Pierre Fabre; Pfizer, Inc.; Zymeworks
        Research funding from: Merck Serono; Merck Sharp & Dohme; Pfizer, Inc.; SIRTEX Medical

      • Eric Van Cutsem, MD, PhD

        Professor of Medicine
        Head of Digestive Oncology
        University Hospital Leuven
        Leuven, Belgium

        Disclosures

        Eric Van Cutsem, MD, PhD has the following relevant financial relationships:
        Consultant or advisor for: AbbVie Inc.; ALX; Array BioPharma; Astellas Pharma, Inc.; AstraZeneca; Bayer; BeiGene (Beijing) Co., Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; GlaxoSmithKline; Incyte Corporation; Ipsen; Merck Sharp & Dohme; Merck KGaA; Mirati; Nordic Bioscience; Novartis; Pierre Fabre; Pfizer, Inc.; Roche; Seagen Inc.; SERVIER; Taiho Pharmaceutical Co., Ltd; Takeda; Terumo Medical Corporation; Zymeworks
        Research funding from: Amgen Inc.; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Ipsen; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER

      • Sebastian Stintzing, MD

        Professor of Medicine
        Head of the Department of Hematology,
        Oncology, and Cancer Immunology (CCM)
        Charité-Universitaetsmedizin Berlin
        Berlin, Germany

        Disclosures

        Sebastian Stintzing, MD, has the following relevant financial relationships:
        Consultant or advisor for: Amgen, Inc.; AstraZeneca; Bayer; Bristol Myers Squibb Company; Eli Lilly and Company; ESAI; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Pharmaceutical Co., Ltd.; Takeda
        Speaker or member of speakers bureau for: Amgen, Inc.; AstraZeneca; Bayer; Bristol Myers Squibb Company; Eli Lilly and Company; ESAI; Isofol; LEO Pharma, Inc.;
        Research funding from: Merck KGaA; Pierre Fabre; SERVIER; Roche

      Editors

      • Keisha Peters, MSc

        Medical Education Director, WebMD Global, LLC

        Disclosures

        Keisha Peters, MSc, has no relevant financial relationships.

      • Eloise Ballard, PhD

        Scientific Content Manager, WebMD Global, LLC

        Disclosures

        Eloise Ballard, PhD, has no relevant financial relationships.

      Compliance Reviewer

      • Leigh Schmidt, MSN, RN, CNE, CHCP

        Associate Director, Accreditation and Compliance, Medscape, LLC

        Disclosures

        Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

      Peer Reviewer

      This activity has been peer reviewed and the reviewer has no relevant financial relationships.

      Accreditation Statements

        For Physicians

      • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

        Contact WebMD Global

      For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

      Instructions for Participation and Credit

      There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

      This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

      Follow these steps to claim a credit certificate for completing this activity:

      1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
      2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

      We encourage you to complete an Activity Evaluation to provide feedback for future programming.

      You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

      *The credit that you receive is based on your user profile.

      From Medscape Education
      CPD

      Molecularly Guided Therapies for Metastatic Colorectal Cancer: Choose Your Marker to Treat

      Authors: Julien Taieb, MD, PhD; Chiara Cremolini, MD, PhD; Harpreet Wasan, MD; Eric Van Cutsem, MD, PhD; Sebastian Stintzing, MDFaculty and Disclosures

      CPD Released: 4/5/2023

      Valid for credit through: 4/5/2024, 11:59 PM EST

      processing....

      Subtítulos en español

       
      « Return to: Molecularly Guided Therapies for Metastatic Colorectal Cancer: Choose Your Marker to Treat
      Earn Credit Download Slides
      • Print
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.